Rituximab as a monotherapy or in combination therapy for the treatment of non-paraneoplastic autoimmune retinopathy

Arash Maleki,1,2 Neerav Lamba,1,2 Lina Ma,1,2 Stacey Lee,1,2 Alexander Schmidt,1,2 C Stephen Foster1–3 1Massachusetts Eye Research and Surgery Institution, 2Ocular Immunology and Uveitis Foundation, Waltham, 3Harvard Medical School, Boston, MA, USA Purpose: To examine the efficacy of rit...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maleki A, Lamba N, Ma L, Lee S, Schmidt A, Foster CS
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Bortezomib Cyclophosphamide Immunomodulatory therapy Non-paraneoplastic autoimmune retinopathy Rituximab Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/6e1b21f8ad054e4580a80e31c6347d48
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6e1b21f8ad054e4580a80e31c6347d48
record_format	dspace
spelling	oai:doaj.org-article:6e1b21f8ad054e4580a80e31c6347d482021-12-02T02:27:06ZRituximab as a monotherapy or in combination therapy for the treatment of non-paraneoplastic autoimmune retinopathy1177-5483https://doaj.org/article/6e1b21f8ad054e4580a80e31c6347d482017-02-01T00:00:00Zhttps://www.dovepress.com/rituximab-as-a-monotherapy-or-in-combination-therapy-for-the-treatment-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Arash Maleki,1,2 Neerav Lamba,1,2 Lina Ma,1,2 Stacey Lee,1,2 Alexander Schmidt,1,2 C Stephen Foster1–3 1Massachusetts Eye Research and Surgery Institution, 2Ocular Immunology and Uveitis Foundation, Waltham, 3Harvard Medical School, Boston, MA, USA Purpose: To examine the efficacy of rituximab as a monotherapy or in combination therapy for the treatment of patients with non-paraneoplastic autoimmune retinopathy. Methods: Twelve eyes of six patients with non-paraneoplastic autoimmune retinopathy who were treated with rituximab and had at least 6 months of follow-up were included. Demographic data, clinical data, visual field parameters, electroretinography parameters, and anti-retinal and anti-optic nerve autoantibody bands were collected from the Massachusetts Eye Research and Surgery Institution database between September 2010 and January 2015. Changes in visual acuity, visual field parameters, electroretinography parameters, and anti-retinal and anti-optic nerve autoantibody bands from the initial visit to the most recent visit were examined. Results: From the initial visit to the last visit, visual acuity was stable in eight (66.7%) eyes. Visual field was stable in six (50%) eyes and improved in two (16.7%) eyes. Electroretinography was stable or improved in eight (66.7%) eyes. The average number of anti-retinal and anti-optic nerve antibody bands was reduced. Conclusion: Stabilization and/or improvement of visual acuity, visual field parameters, and electroretinography parameters were observed in a high number of patients (75%) on rituximab, as a monotherapy (one patient) or in combination therapy. Keywords: birdshot retinochoroidopathy, bortezomib, CD20, cyclophosphamide, HLA-A29, HLA-B27, immunomodulatory therapy, systemic lupus erythematosusMaleki ALamba NMa LLee SSchmidt AFoster CSDove Medical PressarticleBortezomibCyclophosphamideImmunomodulatory therapyNon-paraneoplastic autoimmune retinopathyRituximabOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 11, Pp 377-385 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Bortezomib Cyclophosphamide Immunomodulatory therapy Non-paraneoplastic autoimmune retinopathy Rituximab Ophthalmology RE1-994
spellingShingle	Bortezomib Cyclophosphamide Immunomodulatory therapy Non-paraneoplastic autoimmune retinopathy Rituximab Ophthalmology RE1-994 Maleki A Lamba N Ma L Lee S Schmidt A Foster CS Rituximab as a monotherapy or in combination therapy for the treatment of non-paraneoplastic autoimmune retinopathy
description	Arash Maleki,1,2 Neerav Lamba,1,2 Lina Ma,1,2 Stacey Lee,1,2 Alexander Schmidt,1,2 C Stephen Foster1–3 1Massachusetts Eye Research and Surgery Institution, 2Ocular Immunology and Uveitis Foundation, Waltham, 3Harvard Medical School, Boston, MA, USA Purpose: To examine the efficacy of rituximab as a monotherapy or in combination therapy for the treatment of patients with non-paraneoplastic autoimmune retinopathy. Methods: Twelve eyes of six patients with non-paraneoplastic autoimmune retinopathy who were treated with rituximab and had at least 6 months of follow-up were included. Demographic data, clinical data, visual field parameters, electroretinography parameters, and anti-retinal and anti-optic nerve autoantibody bands were collected from the Massachusetts Eye Research and Surgery Institution database between September 2010 and January 2015. Changes in visual acuity, visual field parameters, electroretinography parameters, and anti-retinal and anti-optic nerve autoantibody bands from the initial visit to the most recent visit were examined. Results: From the initial visit to the last visit, visual acuity was stable in eight (66.7%) eyes. Visual field was stable in six (50%) eyes and improved in two (16.7%) eyes. Electroretinography was stable or improved in eight (66.7%) eyes. The average number of anti-retinal and anti-optic nerve antibody bands was reduced. Conclusion: Stabilization and/or improvement of visual acuity, visual field parameters, and electroretinography parameters were observed in a high number of patients (75%) on rituximab, as a monotherapy (one patient) or in combination therapy. Keywords: birdshot retinochoroidopathy, bortezomib, CD20, cyclophosphamide, HLA-A29, HLA-B27, immunomodulatory therapy, systemic lupus erythematosus
format	article
author	Maleki A Lamba N Ma L Lee S Schmidt A Foster CS
author_facet	Maleki A Lamba N Ma L Lee S Schmidt A Foster CS
author_sort	Maleki A
title	Rituximab as a monotherapy or in combination therapy for the treatment of non-paraneoplastic autoimmune retinopathy
title_short	Rituximab as a monotherapy or in combination therapy for the treatment of non-paraneoplastic autoimmune retinopathy
title_full	Rituximab as a monotherapy or in combination therapy for the treatment of non-paraneoplastic autoimmune retinopathy
title_fullStr	Rituximab as a monotherapy or in combination therapy for the treatment of non-paraneoplastic autoimmune retinopathy
title_full_unstemmed	Rituximab as a monotherapy or in combination therapy for the treatment of non-paraneoplastic autoimmune retinopathy
title_sort	rituximab as a monotherapy or in combination therapy for the treatment of non-paraneoplastic autoimmune retinopathy
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/6e1b21f8ad054e4580a80e31c6347d48
work_keys_str_mv	AT malekia rituximabasamonotherapyorincombinationtherapyforthetreatmentofnonparaneoplasticautoimmuneretinopathy AT lamban rituximabasamonotherapyorincombinationtherapyforthetreatmentofnonparaneoplasticautoimmuneretinopathy AT mal rituximabasamonotherapyorincombinationtherapyforthetreatmentofnonparaneoplasticautoimmuneretinopathy AT lees rituximabasamonotherapyorincombinationtherapyforthetreatmentofnonparaneoplasticautoimmuneretinopathy AT schmidta rituximabasamonotherapyorincombinationtherapyforthetreatmentofnonparaneoplasticautoimmuneretinopathy AT fostercs rituximabasamonotherapyorincombinationtherapyforthetreatmentofnonparaneoplasticautoimmuneretinopathy
_version_	1718402475343478784

Rituximab as a monotherapy or in combination therapy for the treatment of non-paraneoplastic autoimmune retinopathy

Ejemplares similares